Metastatic castration-resistant prostate cancer (CRPC)

Clinical trials for Metastatic castration-resistant prostate cancer (CRPC) explained in plain language.

Never miss a new study

Get alerted when new Metastatic castration-resistant prostate cancer (CRPC) trials appear

Sign up with your email to follow new studies for Metastatic castration-resistant prostate cancer (CRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug aims to outsmart resistant prostate cancer

Disease control Recruiting now

This early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink …

Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

Phase 1 • Sponsor: TechnoGenesys, Inc. • Aim: Disease control

Last updated Jun 27, 2026 11:03 UTC

Metastatic castration-resistant prostate cancer (CRPC)

Get alerted when new Metastatic castration-resistant prostate cancer (CRPC) trials appear

New drug aims to outsmart resistant prostate cancer